The SEC says the drug maker failed to timely inform investors about its merger talks with Salix and Actavis.
Are high levels of inventory at wholesalers indicative of improper accounting of sales?
The Treasury Department's recent anti-inversion measures claim their first victim — Salix Pharmaceuticals' plan to merge with Italy-based Cosmo.
The hue and cry over tax inversions is not stopping companies from proceeding with more mergers that take advantage of the tactic.
